May 9, 2014

Drugmaker Novartis fails to report side effects linked to Tasigna

Novartis Pharma K.K. failed to inform the government of at least 10 suspected cases of serious side effects involving its Tasigna leukemia drug, it was learned Friday. The Health, Labor and Welfare Ministry has opened an investigation into whether the Novartis unit broke the ...

Apr 3, 2014

Heads roll at Novartis over scandal

Swiss pharmaceutical giant Novartis said Thursday it is replacing the top executives at its Japanese unit over allegations that the division hid the existence of serious potential side effects linked to leukemia treatments from regulators. David Epstein, head of the firm’s pharmaceutical division, told ...

Diovan scandal traced to cozy doctor-drugmaker ties

Feb 27, 2014

Diovan scandal traced to cozy doctor-drugmaker ties

The manipulation of clinical research data used to develop the blood pressure drug Diovan sold by Novartis Pharma K.K. has prompted a special squad of Tokyo prosecutors to search the Japanese unit of the Swiss drugmaker as well as the universities that conducted the ...

Feb 19, 2014

Tokyo prosecutors raid Novartis Pharma over drug ads

Tokyo prosecutors raided Novartis Pharma K.K. on Wednesday over its alleged use of exaggerated advertising for a blood pressure-lowering drug, following a criminal complaint filed by the health ministry last month. The ministry claimed that the ads for Diovan cited clinical study reports by ...

Novartis drug data meddling clouds Japan's clinical studies

Oct 3, 2013

Novartis drug data meddling clouds Japan's clinical studies

A health ministry panel is questioning Novartis Pharma K.K.’s use of clinical research data in promoting the sale of Diovan, its drug to lower blood pressure, saying it “could constitute misleading advertisement” after revelations that some of the data were manipulated. The Japanese unit ...

Jul 28, 2013

Question of objectivity

A Kyoto university's announcement that research on blood-pressure drug Diovan was manipulated raises concerns about the drugmaker's objectivity.